Drug & intervention

rucaparib

RxCUI 1862579

Clinical trials23
Recruiting0
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…

Clinical trials

23 shown
CATCH-R: A Rollover Study to Provide Continued Access to RucaparibNCT04676334 · 2021-03-22
COMPLETED
PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell CancersNCT04209595 · 2020-04-08
COMPLETED
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate CancerNCT04253262 · 2020-04-03
ACTIVE_NOT_RECRUITING
A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR GenesNCT04171700 · 2020-01-16
TERMINATED
Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)NCT04179396 · 2019-12-05
COMPLETED
A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)NCT03992131 · 2019-06-28
TERMINATED
A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.NCT03840200 · 2019-06-12
COMPLETED
Rucaparib in Nonmetastatic prOstAte With BRCAnessNCT03533946 · 2019-05-20
TERMINATED
Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast TumorsNCT03911453 · 2019-04-19
COMPLETED
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)NCT03845296 · 2019-04-16
COMPLETED
Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant MesotheliomaNCT03654833 · 2019-01-28
COMPLETED
Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung CancerNCT03559049 · 2018-12-24
TERMINATED
Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene MutationsNCT03413995 · 2018-09-10
COMPLETED
Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair DeficiencyNCT03442556 · 2018-08-24
TERMINATED
Rucaparib and Nivolumab in Patients With Prostate or Endometrial CancerNCT03572478 · 2018-08-14
TERMINATED
A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following ChemotherapyNCT03542175 · 2018-05-23
COMPLETED
An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate CancerNCT03338790 · 2017-12-19
COMPLETED
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene DeficiencyNCT02975934 · 2017-06-13
COMPLETED
A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast CancerNCT03101280 · 2017-04-27
COMPLETED
A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene DeficiencyNCT02952534 · 2017-02-15
COMPLETED
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesNCT02711137 · 2016-05-18
TERMINATED
A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic SignatureNCT02505048 · 2016-03-01
COMPLETED
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 MutationsNCT01074970 · 2010-02-01
COMPLETED

Conditions being studied

Breast Cancer4Prostate Cancer4Metastatic Castration Resistant Prostate Cancer3Ovarian Cancer3Metastatic Castration-Resistant Prostate Cancer2Solid Tumor2ATM Gene Mutation1BRCA1 Gene Mutation1BRCA2 Gene Mutation1Castration Levels of Testosterone1Castration-Resistant Prostate Carcinoma1Deleterious BRCA1 Gene Mutation1Deleterious BRCA2 Gene Mutation1Endometrial Cancer1Epithelial Ovarian Cancer1Extra-Pulmonary Small Cell Carcinomas1Fallopian Tube Cancer1Gynecologic Neoplasms1Homologous Recombination Deficiency1Loss of Heterozygosity1

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.